All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-CN084 | Anti-BCL2L2 (16H12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 16H12 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CN085 | Anti-BCL2L2 (CBLNB-275) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBLNB-275 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CN185 | Anti-BCL2L2 (16H12) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 16H12 | Rat | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CN186 | Anti-BCL2L2 (CBLNB-275) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBLNB-275 | Rat | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ6971 | Anti-BCL2L2 (12BA29) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 12BA29 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ6972 | Anti-BCL2L2 (12BA30) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 12BA30 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ6973 | Anti-BCL2L2 (12BA31) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 12BA31 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ7451 | Anti-BCL2L2 (12BA29) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 12BA29 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ7452 | Anti-BCL2L2 (12BA30) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 12BA30 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ7453 | Anti-BCL2L2 (12BA31) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 12BA31 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION